IVD Medical (1931) H2 2024 earnings summary

Executive summary

• Revenue increased by 2.4% year-over-year to RMB3,162.4 million, with net profit up 12.2% to RMB266.0 million, driven by higher gross profit margins in analysers and after-sales services.

• Adjusted profit for the year (non-GAAP) rose 7.0% to RMB280.4 million, reflecting core operational improvements.

• No final dividend was recommended for 2024.

Financial highlights

• Gross profit grew 11.8% to RMB751.2 million, with gross margin up to 23.8% from 21.7% year-over-year.

• EBITDA increased 19.6% to RMB476.0 million.

• Cash and cash equivalents rose 44.9% to RMB1,774.4 million.

• Total assets increased 15.4% to RMB5,523.9 million.

Outlook and guidance

• Plans to expand product portfolio, distribution network, and hospital coverage to capture IVD market growth.

• Focus on upgrading solution services with data-driven and automated tools, and investing in AI and robotics for future business expansion.

• Continued investment in R&D, especially in mass spectrometry, molecular diagnostics, and microbiology.